Category: Latest News
-
InspireMD Shares Rise on U.S. Rollout of CGuard Prime Carotid Stent
InspireMD Inc. (NASDAQ:NSPR) saw its shares rise 4% in premarket trading after the company officially launched its CGuard Prime carotid stent system in the U.S. market. The commercial debut follows the product’s premarket approval by the U.S. Food and Drug Administration. CGuard Prime is engineered to reduce the risk of embolism both shortly after and…
-
Kazia Therapeutics Shares Surge on Promising Initial Data from Cancer Trial
Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) saw its stock jump 45% after unveiling preliminary data from the first patient enrolled in its Phase 1b study evaluating a new combination therapy for metastatic triple-negative breast cancer. The company highlighted that the patient, a 61-year-old woman, experienced a greater than 50% reduction in circulating tumor cells (CTCs) along…
-
Classover Shares Jump After Boosting Solana Holdings Nearly 300%
Shares of Classover Holdings Inc (NASDAQ:KIDZ) soared 25% following the company’s announcement that it has dramatically increased its reserves of Solana (SOL), a leading blockchain token. The online education firm disclosed that it has grown its SOL holdings by approximately 295% since its last update on June 12, raising the total to 52,067 tokens. According…
-
Evoke Pharma Shares Jump 50% Following Patent Approval for GIMOTI
Evoke Pharma Inc (NASDAQ:EVOK) saw its stock soar 50% after the specialty pharma company received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application covering GIMOTI, its treatment for gastroparesis. The newly allowed patent application is a continuation of U.S. Patent No. 11,517,545 and strengthens Evoke’s intellectual property protection…
-
Rhythm Pharmaceuticals Shares Jump Following Promising Phase 2 Data for Obesity Drug
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) saw its stock rise by 10% after unveiling encouraging topline results from its Phase 2 clinical trial assessing bivamelagon, a novel oral melanocortin-4 receptor agonist, in patients suffering from acquired hypothalamic obesity. The biopharma company revealed that bivamelagon produced statistically significant and clinically meaningful decreases in body mass index (BMI) after…
-
Dow Jones, S&P, Nasdaq, U.S. Stocks Set for a Positive Start Amid Trade Deal Optimism and Fed Watch
U.S. stock futures indicate a modest gain for Wednesday’s open as investors look to bounce back following a mostly flat and volatile session on Tuesday. Market sentiment is buoyed by reports that the U.S. and European Union are closing in on a trade agreement, potentially involving tariffs higher than those applied to the U.K. The…
-
Tandem Diabetes Shares Drop Following Citi Downgrade Over Rising Competition
Tandem Diabetes Care (NASDAQ:TNDM) saw its stock decline by 5% Wednesday morning after Citi downgraded the company from Neutral to Sell, citing increasing challenges from competitors. Analyst Joanne Wuensch cut her price target sharply, lowering it from $24 to $14, suggesting a downside of about 16% compared to Tuesday’s closing price of $16.62. The downgrade…
-
ProKidney Shares Soar After Citi Lifts Price Target to $9
Shares of ProKidney Corp. (NASDAQ:PROK) jumped 65% in pre-market trading Wednesday, extending the dramatic rally seen on Tuesday, when the stock surged over 500% following encouraging clinical trial results. The price boost followed Citi’s decision to raise its price target from $6 to $9, driven by stronger-than-anticipated topline outcomes from the Phase 2 REGEN-007 trial.…
-
Aehr Test Systems Stock Sinks 20% as Revenue Drops and Company Posts Quarterly Loss
Shares of Aehr Test Systems (NASDAQ:AEHR) tumbled 20% after the company reported a year-over-year decline in revenue for its fiscal fourth quarter, along with a swing to a net loss. The semiconductor testing equipment maker generated $14.1 million in revenue for the quarter, down from $16.6 million in the same period a year earlier. The…
-
Merck to Acquire Verona Pharma in $10 Billion Deal to Expand Respiratory Drug Portfolio
Merck (NYSE:MRK) announced Wednesday it has struck a definitive agreement to acquire Verona Pharma PLC ADR (NASDAQ:VRNA) in a transaction valued at approximately $10 billion, or $107 per American Depositary Share. The move strengthens Merck’s position in the respiratory and cardio-pulmonary space by adding Ohtuvayre (ensifentrine) to its pipeline — a newly approved, first-in-class dual…